Unbound MEDLINE

Simultaneous determination of anti-diabetes/anti-obesity drugs by LC/PDA, and targeted analysis of sibutramine analog in dietary supplements by LC/MS/MS. Biomedical chromatography : BMC [Biomed Chromatogr] Journal article

 
TitleSimultaneous determination of anti-diabetes/anti-obesity drugs by LC/PDA, and targeted analysis of sibutramine analog in dietary supplements by LC/MS/MS.
Author(s)Kim SH, Lee J, Yoon T, Choi J, Choi D, Kim D, Kwon SW 
InstitutionCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151742, Korea.
SourceBiomed Chromatogr 2009 May 27.
AbstractThe safety of dietary supplements is questionable as there have been occasional reports of products contaminated with illegal adulterants. The present study was carried out to develop trustworthy methodologies to screen for six anti-diabetic drugs (phenformin, rosiglitazone, glipizide, glimepiride, glybenclamide and gliclazide) and six anti-obesity drugs (ephedrine, fenfluramine, T3, T4, fluoxetine and sibutramine) in dietary supplements. A simultaneous determination method of the 12 drugs by liquid chromatography coupled with a photodiode array (LC/PDA) was established and was validated for linearity (r(2) > 0.99), precision (RSD <13.3%), recoveries (88.8-115.9%) and reproducibility. Sibutramine and its analogs, N-desmethylsibutramine, were subject to further investigation by LC/MS/MS because they were one of the major illegal adulterants. Our proposed method to monitor illegal drug adulterations in dietary supplements using LC/PDA is a simple and reliable, and therefore applicable to routine drug-adulteration screening. Copyright (c) 2009 John Wiley & Sons, Ltd.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19475544
  
Advertise on this site.